Early Access

Back to ABT

ABBOTT LABORATORIES Cash & Equivalents 2006-2025 | ABT

Beta

What is cash & equivalents?

Cash and cash equivalents can be defined as the most liquid assets on a company's balance sheet, including cash on hand and short-term investments maturing within 90 days.

What is ABBOTT LABORATORIES's current cash & equivalents?

ABBOTT LABORATORIES (ABT) annual cash & equivalents for 2024 was $7.62B, a 10.44% increase from 2023. ABBOTT LABORATORIES cash & equivalents for the quarter ending September 30, 2025 was $7.51B.

What was ABBOTT LABORATORIES's cash & equivalents in 2023?

ABBOTT LABORATORIES annual cash & equivalents for 2023 was $6.90B, a 30.22% decline from 2022.

What was ABBOTT LABORATORIES's cash & equivalents in 2022?

ABBOTT LABORATORIES annual cash & equivalents for 2022 was $9.88B, a 0.85% increase from 2021.

What is ABBOTT LABORATORIES's 5-year cash & equivalents CAGR?

ABBOTT LABORATORIES cash & equivalents grew at a compound annual growth rate (CAGR) of 14.56% from FY2019 to FY2024, going from $3.86B to $7.62B over 5 years.

Cash & Equivalents History

Year-over-year comparison from 10-K annual reports

Key Statistics
Trend Direction
Stable
CAGR+14.6%
FY2019
$3.86B
FY2024
$7.62B
06070809101112131415161718192021222324
5 years selected
Cash & Equivalents History
PeriodValueChangeSource
FY2024$7.62B+10.4%10-K
FY2023$6.90B-30.2%10-K
FY2022$9.88B+0.8%10-K
FY2021$9.80B+43.3%10-K
FY2020$6.84B+77.2%10-K
FY2019$3.86B+0.4%10-K
FY2018$3.84B-59.1%10-K
FY2017$9.41B-49.5%10-K
FY2016$18.62B+272.3%10-K
FY2015$5.00B+23.1%10-K
FY2014$4.06B+16.9%10-K
FY2013$3.48B-67.8%10-K
FY2012$10.80B+58.5%10-K
FY2011$6.81B+86.8%10-K
FY2010$3.65B-58.6%10-K
FY2009$8.81B+114.2%10-K
FY2008$4.11B+67.4%10-K
FY2007$2.46B+371.3%10-K
FY2006$521.2M-10-K
Company: ABBOTT LABORATORIESTicker: ABTSector: HealthcareIndustry: Pharmaceutical PreparationsView company profile →